Ferumoxytol-Enhanced MRI in Adult/Pedi Sarcomas

Withdrawn before enrolling · Not applicable

Conditions studied: Soft Tissue Sarcoma

In brief

This research study is a pilot study to evaluate a new contrast agent, ferumoxytol, for the purpose of imaging lymph node metastases in patients with soft tissue sarcoma. This contrast agent is an investigational drug. "Investigational" means that the drug is still being studied and that research doctors are trying to find out more about it. It also means that the FDA has not approved ferumoxytol for this use. This drug has been used to image adults with other forms of cancer, however, it has only been used to image a small number of pediatric patients. Ferumoxytol has never been used to image sarcoma.

Key facts

Study ID
NCT01663090
Run by
Dana-Farber Cancer Institute
People needed
0
Starts
2012-09-01
Expected to finish
2016-11-01
Last updated by the study team
2020-10-19

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.